Ortivus AB ser. A - Asset Resilience Ratio
Ortivus AB ser. A (ORTI-A) has an Asset Resilience Ratio of 12.53% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Ortivus AB ser. A (ORTI-A) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Ortivus AB ser. A's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Ortivus AB ser. A to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Ortivus AB ser. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ortivus AB ser. A market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr8.89 Million | 12.53% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr8.89 Million | 12.53% |
Asset Resilience Insights
- Moderate Liquidity: Ortivus AB ser. A has 12.53% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Ortivus AB ser. A Industry Peers by Asset Resilience Ratio
Compare Ortivus AB ser. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087 |
Medical Instruments & Supplies | 9.87% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Pegavision
TW:6491 |
Medical Instruments & Supplies | 17.14% |
|
Tarsons Products Limited
NSE:TARSONS |
Medical Instruments & Supplies | 0.47% |
|
SciVision Biotech Inc
TW:1786 |
Medical Instruments & Supplies | 7.81% |
|
Nyxoah
BR:NYXH |
Medical Instruments & Supplies | 12.40% |
|
I.Ceram SA
PA:ALICR |
Medical Instruments & Supplies | -1.61% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
Annual Asset Resilience Ratio for Ortivus AB ser. A (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Ortivus AB ser. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.53% | Skr8.89 Million ≈ $956.49K |
Skr70.93 Million ≈ $7.63 Million |
+1.14pp |
| 2024-12-31 | 11.39% | Skr7.28 Million ≈ $783.55K |
Skr63.91 Million ≈ $6.88 Million |
+9.62pp |
| 2023-12-31 | 1.77% | Skr1.29 Million ≈ $138.72K |
Skr72.71 Million ≈ $7.82 Million |
-6.69pp |
| 2022-12-31 | 8.46% | Skr7.60 Million ≈ $817.56K |
Skr89.75 Million ≈ $9.66 Million |
-22.05pp |
| 2021-12-31 | 30.52% | Skr22.11 Million ≈ $2.38 Million |
Skr72.46 Million ≈ $7.80 Million |
-4.98pp |
| 2020-12-31 | 35.50% | Skr23.62 Million ≈ $2.54 Million |
Skr66.55 Million ≈ $7.16 Million |
+10.63pp |
| 2019-12-31 | 24.87% | Skr8.69 Million ≈ $935.08K |
Skr34.94 Million ≈ $3.76 Million |
+12.52pp |
| 2018-12-31 | 12.34% | Skr3.42 Million ≈ $367.94K |
Skr27.70 Million ≈ $2.98 Million |
+7.19pp |
| 2017-12-31 | 5.16% | Skr1.78 Million ≈ $191.66K |
Skr34.54 Million ≈ $3.72 Million |
-0.88pp |
| 2016-12-31 | 6.03% | Skr2.85 Million ≈ $306.81K |
Skr47.25 Million ≈ $5.08 Million |
+5.28pp |
| 2009-12-31 | 0.75% | Skr1.24 Million ≈ $133.34K |
Skr164.13 Million ≈ $17.66 Million |
+0.01pp |
| 2008-12-31 | 0.75% | Skr1.35 Million ≈ $145.82K |
Skr181.28 Million ≈ $19.51 Million |
-2.48pp |
| 2007-12-31 | 3.23% | Skr8.19 Million ≈ $881.16K |
Skr253.45 Million ≈ $27.27 Million |
+0.90pp |
| 2006-12-31 | 2.33% | Skr7.80 Million ≈ $838.97K |
Skr333.90 Million ≈ $35.93 Million |
-0.57pp |
| 2005-12-31 | 2.91% | Skr10.36 Million ≈ $1.11 Million |
Skr356.27 Million ≈ $38.34 Million |
-- |
About Ortivus AB ser. A
Ortivus AB (publ) develops and commercializes medical technology solutions and e-health for healthcare industry in Sweden and internationally. The company offers MobiMed Monitor that monitor and shares vital signs and ECG; MobiMed ePR, an electronic patient record system for documentation of treatment and events; MobiMed enRoute, a navigation, case management, and mass casualty management; MobiMe… Read more